By Fineline Cube Shanghai-based multi-omics specialist Biotree has raised nearly RMB100 million ($14.8 million) in a Series A financing round led by Qiming Venture Partners. The funds will support platform expansion, R&D, production, and market promotion.
Company Background
Founded in 2012, Biotree conducts metabolomic and proteomic research on human, animal, plant, and microbial samples. The firm translates research into clinical and health screening products, leveraging its integrated platform for scientific services, pharma support, clinical mass spectrometry, and big data analytics.
Platform Expansion
Biotree plans to apply innovative mass spectrometry technology in life sciences and medical health, focusing on clinical diagnostics and health screening solutions. The Series A funding will accelerate its R&D and commercialization efforts.-Fineline Info & Tech